Avian L. reuteri strains show promise, but raise AMR questions

A new Animals study spotlights two avian-derived Limosilactobacillus reuteri strains as possible next-generation poultry probiotics, but with an important caveat. The strains, LBM-Ti195 and LBM-Ti173, were isolated from broiler cecal microbiota and demonstrated in vitro antibacterial activity against pathogens that matter in veterinary and food safety settings, including Clostridium perfringens type A, Campylobacter jejuni, Listeria monocytogenes, and Staphylococcus aureus. The same study found that both strains produced folate and could use fructooligosaccharides and inulin, supporting potential synbiotic applications. (citedrive.com)

The work lands in a familiar industry context: poultry producers and animal health researchers are still looking for credible antimicrobial alternatives as pressure grows to reduce routine antibiotic use. L. reuteri is already a species of interest in poultry because it is a common gut inhabitant in chickens, and earlier studies have linked chicken-derived strains to reuterin production, microbiota modulation, and inhibition of enteric bacteria in broiler models. Reviews published in the past two years have also described L. reuteri as a promising probiotic candidate in chickens, while broader comparative genomics work has emphasized that host-adapted, strain-level differences can strongly shape function and safety. (link.springer.com)

In the new paper, the authors combined phenotypic testing with comparative genomics. They reported that anti-S. aureus activity increased by more than 10% under modified cultivation conditions, and genomic analysis pointed to an M23-family metallopeptidase as one possible contributor to pathogen inhibition. They also identified a complete predicted folate biosynthesis pathway, which strengthens the biological plausibility of the folate-production findings. In addition, CAZyme annotation showed higher copy numbers of glycosyltransferases GT2 and GT4 than in reference strains, suggesting differences in cell-surface carbohydrate metabolism and possibly exopolysaccharide-associated traits. (citedrive.com)

The most consequential finding for downstream development may be the safety signal. Although the strains showed no hemolytic activity and no conserved virulence factors under the tested conditions, both displayed phenotypic tetracycline resistance. The genomic analysis further identified an acquired tetW gene in a putative plasmid-associated context. That matters because recent genomics literature on L. reuteri has stressed that strain-specific safety assessment is necessary before food, feed, or therapeutic use, particularly when antimicrobial resistance genes are present or potentially mobile. (citedrive.com)

There does not appear to be a separate institutional press release or broad industry reaction published so far, but the findings fit squarely within current expert discussion around host-adapted probiotics and post-antibiotic production strategies in poultry. Recent reviews have highlighted two especially relevant themes: first, that L. reuteri can generate antimicrobial metabolites such as reuterin, and second, that folate production and prebiotic compatibility could expand the value proposition beyond pathogen suppression alone. That said, those same reviews also underscore that metabolite production is highly strain- and condition-dependent, so performance in vitro does not guarantee field efficacy. (tandfonline.com)

Why it matters: For veterinarians, nutrition teams, and poultry health managers, this is a useful reminder that the next wave of probiotic candidates will likely be judged on two tracks at once: functional performance and resistance risk. A strain that inhibits C. perfringens and supports gut nutrition through folate production is attractive in a sector still dealing with enteric disease pressure and antimicrobial stewardship demands. But a candidate carrying an acquired tetracycline resistance determinant, especially in a potentially plasmid-associated setting, faces a higher bar for translational development, regulatory review, and risk assessment. In practice, that means microbiome-based feed strategies may become more sophisticated, but also more dependent on whole-genome scrutiny and transfer-risk testing before veterinarians can feel confident recommending them. (citedrive.com)

What to watch: The next milestones are likely to be controlled in vivo broiler studies, confirmation of whether the resistance determinant is transferable, and any early movement toward zootechnical feed-additive development. If those studies show efficacy without unacceptable antimicrobial resistance risk, these strains could become part of a more targeted synbiotic or probiotic toolkit for poultry production. For now, the paper is best read as a promising early-stage signal, not a ready-for-field product story. (citedrive.com)